165 related articles for article (PubMed ID: 29443649)
1. Use of Charity Financial Assistance for Novel Oral Anticancer Agents.
Olszewski AJ; Zullo AR; Nering CR; Huynh JP
J Oncol Pract; 2018 Apr; 14(4):e221-e228. PubMed ID: 29443649
[TBL] [Abstract][Full Text] [Related]
2. Financial Eligibility Criteria and Medication Coverage for Independent Charity Patient Assistance Programs.
Kang SY; Sen A; Bai G; Anderson GF
JAMA; 2019 Aug; 322(5):422-429. PubMed ID: 31386135
[TBL] [Abstract][Full Text] [Related]
3. The Role of Patient Financial Assistance Programs in Reducing Costs for Cancer Patients.
Zullig LL; Wolf S; Vlastelica L; Shankaran V; Zafar SY
J Manag Care Spec Pharm; 2017 Apr; 23(4):407-411. PubMed ID: 28345445
[TBL] [Abstract][Full Text] [Related]
4. Barriers to receipt of novel oral oncolytics: A single-institution quality improvement investigation.
Wang AA; Tapia C; Bhanji Y; Campbell C; Larsen D; Gross D; Ganatra S; Qodsi M; Tellez C; Jain S
J Oncol Pharm Pract; 2020 Mar; 26(2):279-285. PubMed ID: 30943846
[TBL] [Abstract][Full Text] [Related]
5. Out-of-Pocket and Health Care Spending Changes for Patients Using Orally Administered Anticancer Therapy After Adoption of State Parity Laws.
Dusetzina SB; Huskamp HA; Winn AN; Basch E; Keating NL
JAMA Oncol; 2018 Jun; 4(6):e173598. PubMed ID: 29121177
[TBL] [Abstract][Full Text] [Related]
6. Adherence and out-of-pocket costs among Medicare beneficiaries who are prescribed oral targeted therapies for advanced prostate cancer.
Caram MEV; Oerline MK; Dusetzina S; Herrel LA; Modi PK; Kaufman SR; Skolarus TA; Hollenbeck BK; Shahinian V
Cancer; 2020 Dec; 126(23):5050-5059. PubMed ID: 32926427
[TBL] [Abstract][Full Text] [Related]
7. Association of Patient Out-of-Pocket Costs With Prescription Abandonment and Delay in Fills of Novel Oral Anticancer Agents.
Doshi JA; Li P; Huo H; Pettit AR; Armstrong KA
J Clin Oncol; 2018 Feb; 36(5):476-482. PubMed ID: 29261440
[TBL] [Abstract][Full Text] [Related]
8. Out-of-Pocket Spending and Financial Burden Among Medicare Beneficiaries With Cancer.
Narang AK; Nicholas LH
JAMA Oncol; 2017 Jun; 3(6):757-765. PubMed ID: 27893028
[TBL] [Abstract][Full Text] [Related]
9. Targeting Financial Toxicity in Oncology Specialty Pharmacy at a Large Tertiary Academic Medical Center.
Farano JL; Kandah HM
J Manag Care Spec Pharm; 2019 Jul; 25(7):765-769. PubMed ID: 31232209
[TBL] [Abstract][Full Text] [Related]
10. Characterizing Out-of-Pocket Payments and Financial Assistance for Patients Prescribed Abiraterone and Enzalutamide at an Academic Cancer Center Specialty Pharmacy.
Jeong AY; Schwartz EB; Roman AR; McDevitt RL; Oerline MK; Henry E; Veenstra CM; Caram MEV
JCO Oncol Pract; 2022 Feb; 18(2):e284-e292. PubMed ID: 34491783
[TBL] [Abstract][Full Text] [Related]
11. Medicare Beneficiaries Face Growing Out-Of-Pocket Burden For Specialty Drugs While In Catastrophic Coverage Phase.
Trish E; Xu J; Joyce G
Health Aff (Millwood); 2016 Sep; 35(9):1564-71. PubMed ID: 27605634
[TBL] [Abstract][Full Text] [Related]
12. Rising Prices of Targeted Oral Anticancer Medications and Associated Financial Burden on Medicare Beneficiaries.
Shih YT; Xu Y; Liu L; Smieliauskas F
J Clin Oncol; 2017 Aug; 35(22):2482-2489. PubMed ID: 28471711
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceutical assistance programs for cancer patients in the era of orally administered chemotherapeutics.
Mitchell A; Muluneh B; Patel R; Basch E
J Oncol Pharm Pract; 2018 Sep; 24(6):424-432. PubMed ID: 28714357
[TBL] [Abstract][Full Text] [Related]
14. A descriptive study of patients receiving foundational financial assistance through local specialty pharmacies.
Zhu J; Odebralski R; Boghani S; Walley C; Koen F; Conley C; Kirkham HS
Am J Manag Care; 2018 Mar; 24(5 Suppl):S80-S84. PubMed ID: 29620815
[TBL] [Abstract][Full Text] [Related]
15. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
Dusetzina SB; Keating NL
J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
[TBL] [Abstract][Full Text] [Related]
16. Association Between Copayment Assistance, Insurance Type, Prior Authorization, and Time to Receipt of Oral Anticancer Drugs.
Lichtenstein MRL; Beauchemin MP; Raghunathan R; Lee S; Doshi SD; Law C; Accordino MK; Elkin EB; Wright JD; Hershman DL
JCO Oncol Pract; 2024 Jan; 20(1):85-92. PubMed ID: 38033273
[TBL] [Abstract][Full Text] [Related]
17. Effect of an expenditure cap on low-income seniors' drug use and spending in a state pharmacy assistance program.
Bishop CE; Ryan AM; Gilden DM; Kubisiak J; Thomas CP
Health Serv Res; 2009 Jun; 44(3):1010-28. PubMed ID: 19291168
[TBL] [Abstract][Full Text] [Related]
18. Out-of-pocket health spending by poor and near-poor elderly Medicare beneficiaries.
Gross DJ; Alecxih L; Gibson MJ; Corea J; Caplan C; Brangan N
Health Serv Res; 1999 Apr; 34(1 Pt 2):241-54. PubMed ID: 10199672
[TBL] [Abstract][Full Text] [Related]
19. Influence of medical insurance schemes and charity assistance projects on regular prophylaxis treatment of the boys with severe haemophilia A in China.
Li Z; Wu J; Zhao Y; Liu R; Li K; Zhou Y; Wu R; Yang R; Zhang X; Lian S; Hu Q; Li X; Gu J; Zhou R; Sun J; Li C; Xu W; Poon MC; Xiao J
Haemophilia; 2018 Jan; 24(1):126-133. PubMed ID: 29148258
[TBL] [Abstract][Full Text] [Related]
20. Cost sharing for oral lenvatinib among commercially insured patients.
Liang MI; Chen L; Aviki EM; Wright JD
Am J Manag Care; 2024 Mar; 30(3):114-117. PubMed ID: 38457819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
